We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Teva Pharmaceuticals is back on the hook for $235 million in damages for infringing on GlaxoSmithKline’s patent for its blood pressure drug Coreg (carvedilol), thanks to a federal appeals court ruling. Read More
The deal gives BMS mavacamten, MyoKardia’s investigational treatment for obstructive hypertrophic cardiomyopathy, a chronic heart disease afflicting up to 200,000 individuals in the U.S. and the EU. Read More
AbbVie, Abbott Laboratories, Unimed Pharmaceuticals and Besins Healthcare are off the hook for $448 million they would have had to pay to the Federal Trade Commission (FTC), thanks to a favorable ruling by a federal appeals court. Read More
The Serum Institute of India (SII) has announced it will produce up to 100 million additional COVID-19 vaccine doses through its collaboration with the Bill & Melinda Gates Foundation and Gavi, the Vaccine Alliance to supply India and lower income nations. Read More
J&J last week began the largest phase 3 trial of a COVID-19 vaccine to date, in which it aims to enroll 60,000 participants across eight countries. Read More
A federal court of appeals has rejected a novel plan that would have brought every community in the U.S. into a class-action suit along with 1,300 cities and counties that are suing opioid makers. Read More
Humanigen has teamed up with Massachusetts-based Thermo Fisher Scientific, which will help manufacture the drug substance for Humanigen’s COVID-19 monoclonal antibody lenzilumab. Read More